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Abstract
Background: The Bath Ankylosing Spondylitis Functional Index (BASFI) has been commonly used in rheumatology
to quantify functional disability in patients with Ankylosing Spondylitis (AS). Our aim was to evaluate the
discriminating power of BASFI and determine the best cutoff score of this index in the general population
compared with AS patients.
Methods: A cross-sectional study that included 200 patients suffering from AS and 223 subjects from the general
population matched for age and sex was carried-out. The discriminating power of the BASFI by strata of age was
evaluated by the area under the Receiver Operating Characteristic curve and the best cutoff was determined by
the Youden index.
Results: The mean age of the general population was 39 ± 12 years. 76.7% of them were male. The median BASFI
of the healthy subjects and patients was 0.2 and 4.5 (P < 0.001) respectively. The best cutoff of BASFI was 1.5 with
a sensitivity of 86% and a specificity of 90%. In the age group of 18-29 years, the best cutoff of the BASFI was 0.9
with a sensitivity of 93% and a specificity of 94%. In the age group of 30-50 years, the best cutoff of the BASFI was
1.5 with a sensitivity of 84% and a specificity of 88%. For those over 50 years of age, the best cutoff of the BASFI
was 2.5 with a sensitivity of 84% and a specificity of 97%.
Conclusions: This study suggests that the discriminating power of BASFI is considered good at any age. The best
cutoff of this index increased as age increases as functional disability is associated in part with lifestyle choices and
increases with age. The cutoff values of the BASFI that we have presented could be used as a reference
benchmark for both clinical practice and research.
Background
The Bath Ankylosing Spondylitis Functional Index
(BASFI) was developed more than a decade ago to mea-
sure functional disability of patients suffering from
Ankylosing Spondyltis (AS) [1] and subsequent out-
comes following therapy. The clinimetric validity and
the usefulness of BASFI in cohort studies of patients
with spondyloarthopathies are firmly established [2-4].
This index can contribute markedly to efficacy evalua-
tions in cohort studies, as it exhibits accurate sensitivity
to change and has been shown to have an acceptable
test-retest reliability and internal validity [5]. Previous
studies have shown the validity of several translations of
BASFI, including the Arabic and Moroccan dialectal ver-
sion [6,7] for use in our patients with AS. The Assess-
ment of SpondyloArthritis international Society (ASAS)
recommends BASFI [1] or Dougados Functional Index
(DFI) [8] for the assessment of physical functioning in
patients with AS [9,10]. The clinimetric properties of
these instruments have been shown to be acceptable
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in a large population of AS subjects [4,12,13]. However,
disability measured by BASFI has not been reported in
the general population of adults. Therefore, we con-
ducted a cross-sectional study to evaluate the discrimi-
nating power of BASFI and determine the best cutoff
score of this index in the general population compared
with AS patients living in the same area and matched
for age and sex.
Patients and methods
Patients with AS
El Ayachi Hospital is the main Moroccan rheumatology
university center in the Rabat -Sale area. All AS patients
refereed to this center for diagnosis or follow-up during
January to April 2010 were recruited for this study.
Patients with AS fulfilled the modified New York criteria
[14]. Patients under 18 years of age were excluded from
the study.
Controls
300 healthy subjects from the general population were
investigated. In order to match the AS patient group by age
and sex, the general population sample was designed to
have a mean age of 39 years and to include 75% male, but
was otherwise random. All subjects in the control group
were living in the same geographic area and were recruited
by announcements at the Faculties of the University of
Rabat, hospitals, in various public institutions and senior
residences. Healthy subjects diagnosed with any pulmonary,
cardiovascular, neurological or rheumatological comorbid-
ity affecting their ability to do daily activities were excluded
from the study. Subjects who replied to the announcements
were selected so that 223 subjects from the general popula-
tion were analyzed within each of the following age cate-
gories: 18-29, 30-50, and > 50 years. Subjects in the control
group were matched for age and sex to AS patients. Within
each age-sex stratum, the sampling process was purely ran-
dom assuring representativeness.
The study protocol was approved by the ethics com-
mittee of the Mohamed V University in Rabat (Faculty of
Medicine and Pharmacy). All patients and healthy con-
trols gave written informed consent before participating
in the study according to the Declaration of Helsinki.
The subjects completed a questionnaire comprising a
complete copy of BASFI and information on socio-
demographic characteristics such as age, sex, height and
weight for calculating the body mass index (BMI; weight
(kg)/height (m
2)), smoking status, level of education and
physical activity. Patients with AS were also asked to fill
out a questionnaire consisting of the Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) score (0-
10), nocturnal and global pain assessed on a 0-100 mm
visual analog scale (VAS) and disease duration.
Bath ankylosing spondylitis functional index
BASFI is a visual analog scale (VAS) index, whereby the
patient rates his/her ability to perform tasks (BASFI) by
marking a vertical line on a 100 mm horizontal line. It
consists of ten tasks lines to assess the degree of diffi-
culty of performing each task. The tasks are: (1) putting
on socks, (2) bending forward to pick up a pen, (3)
reaching a high shelf, (4) getting up from an armless
chair, (5) getting up from the floor from lying supine,
(6) standing unsupported, (7) climbing steps without a
handrail, (8) looking over their shoulders, (9) performing
physically demanding activities, and (10) doing a full
day’s activities. The total BASFI score is calculated by
adding all ten scores and dividing by 10. The validity
and reliability of the Moroccan version of BASFI has
been established previously [6].
Statistical analysis
Descriptive statistics were used to describe the study
sample. Differences in mean and median BASFI between
the two groups (patients and general population) were
determined using Student’s t-test and Chi Square test.
The discriminating power of BASFI by strata of age was
evaluated by the area under the Receiver Operating
Characteristic (ROC) curve [AUC] and the best cutoff
point was determined by the Youden index (better sen-
sitivity and specificity). Analyses were performed with
SPSS Software version 10,0
Results
Characteristics of patient population
A total of 200 patients with AS were recruited for this
study. The mean age of the patients was 39.1 years
(Standard deviation (SD) 12.6; range: 18-67 years). 76.5%
of the selected subjects were male, and the mean disease
duration was 10.6 years (SD 7.9). At the time of the
study, the level of global and nocturnal pain evaluated
on a 0-100 mm VAS was 46 (SD 23) and 39 (SD 29)
respectively and the mean BASDAI was 4.08 (SD 2.23).
A total of 90% of the patients were on non-steroidal
anti-inflammatory drugs while 15% of the patients were
being treated by anti-tumor-necrosis factora.
Characteristics of control population
A total of 223 control subjects were enrolled in the
study. The mean age of the controls was 39 years (SD
12 years). 76.7% of them were male. The characteristics
of patients and controls are shown in Table 1.
Comparison of disability
Overall, the median BASFI of the healthy subjects and
patients was 0.2 (range 0-4.7) and 4.5 (range 1-10) (P <
0.001) respectively. In the control group, the median
BASFI for those between 18 and 29 years of age was 0.0
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group of 30-50 years and to 0.3 (range: 0-3.9) in con-
trols aged more than 50 years.
Overall, the area under the ROC curve (AUC) (95%
confidence interval [CI]) of BASFI was 0.94 (0.92-0.96).
The best cutoff was 1.5 with a sensitivity of 86% and a
specificity of 90% (Figure 1).
The discriminating power and the cutoff points of the
BASFI in the general population compared to AS
patients according to the ROC curve were evaluated in
age stratum (Table 2)
Relationship between BASFI, pain, disease activity
(BASDAI), BMI, education, and physical activity
In the patient group, BASFI was significantly correlated
with pain score (r = 0.47; P < 0.001), the BASDAI (r =
0.58; P < 0.001), physical activity (r = - 0.21; P = 0.02)
and with the BMI (r = 0.22; P = 0.02). However, no sig-
nificant correlation between BASFI, age, sex, smoking
status and level of education was noted. In the general
population, functional disability (BASFI) was highly cor-
related with female sex (r = 0.20; P = 0.002), increasing
age (r = 0.24; P < 0.001) and education (r = - 0.31; P <
0.001). A significant correlation was observed between
BMI and BASFI (r = 0.16; P = 0.01) in both men and
women.
Discussion
Although BASFI is a widely applied tool to measure
functional impairment in patients with AS, the compar-
ability of BASFI across clinical populations has been
hampered by the absence of normative data. Moreover,
differentiation between age-related declines in function-
ing and those that are disease-related requires normative
data (i.e., BASFI in ‘normal’ general populations as
opposed to patient groups). So, we concluded that it
made sense to identify levels of disability that are higher
than could reasonably be expected in the general popu-
lation. This will help the clinician to differentiate
between the disability resulting from the disease versus
the “normal-for-age” decrease in functioning. For exam-
ple, if a man with AS aged 35 years old and a 75 year
-old man with the same disease had a BASFI score of 3,
would that mean that the level of disability due to their
AS was the same? Indeed, both had some difficulties in
their day-to-day activities but it was not possible to
determine whether the level of the disability in these
cases was different from that of people of the same age
and sex in general. Therefore, the reference values of
BASFI in the general population presented in this study
may contribute to better understanding of BASFI scores
in patients with AS. At present, the capacity to bench-
mark a patient’s health status against that of age- and
gender matched peers in the general population exists
Table 1 Characteristics of AS patients and controls
AS Patients Controls P
(n = 200) (n = 223)
Age, mean ± SD years 39.1 ± 12.6 39 ± 12 NS
Age groups (years), No
18-29 58 69 NS
30-50 103 106 NS
>5 0 3 9 4 8 N S
Male sex, n (%) 153 (76.5) 171 (76.7) NS
BMI, mean ± SD years 28.2 ± 5.7 29.7 ± 5.3 0.01
Disease duration, mean ± SD years 10.6 ± 7.9 -
Global pain, (VAS, 0-100 mm) 46 ± 23 -
Nocturnal pain, (VAS, 0-100 mm) 39 ± 29 -
BASDAI (0-10 scale), mean ± SD 4.08 ± 2.23 -
BASFI (0-10 scale), median (range) 4.5 (1-10) 0.2 (0-4.7) < 0.001
AS: ankylosing spondylitis, BASDAI: Bath Ankylosing Spondylitis Disease
Activity Index, BASFI: Bath Ankylosing Spondylitis Functional Index, BMI: body
mass index, NS: not significant, VAS: visual analog scale.
Figure 1 ROC curve illustrating the discriminating power of the
BASFI between AS patients and general population.
Table 2 The discriminating power of the BASFI by age
stratum according to the ROC curve
AUC
(CI:95%)
Cutoff
point
Sensitivity
(%)
Specificity
(%)
BASFI; 18-29
years
0.96
(0.93 - 0.99)
0.9 93 94
30-50 years 0.92
(0.89 - 0.96)
1.5 84 88
> 50 years 0.96
(0.93 - 0.99)
2.5 84 97
AUC: area under the curve ROC, BASFI: Bath Ankylosing Spondylitis Functional
Index; CI: confidence interval, ROC: Receiver Operating Characteristic
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AUSCAN indices [18]. Thus, our report is among the
few in the English medical literature that identifies the
discriminating power of BASFI after stratification by age
and determines the best cutoff of this index in the gen-
eral population compared with AS patients. Results were
expressed using a ROC curve and cutoffs for designating
a significant level of disability.
Overall, the best cutoff of BASFI was 1.5 with a good
sensitivity and specificity. This result indicates that dis-
ability according to BASFI (0-10) is defined as a BASFI
of more than 1.5 irrespective of age and sex. If we divide
the population based on age-groups, we observed age-
related increases in disability, which is congruent with
previously published observations with the SF-36, HAQ,
WOMAC, and AUSCAN indices which show similar
trends, particularly when the age increases. In fact, in
the age group of 18-29 years, the best cutoff of BASFI
permitting to discriminate patients and subjects from
the general population was 0.9 with an acceptable sensi-
tivity and specificity. This cutoff of disability increases
to 1.5 in the age group of 30-50 years and to 2.5 in the
age group > 50 years.
There is a little consensus on what constitutes the
cutoff score for designating a significant level of disabil-
ity. We believe that any of the mean values as well as
the median and other percentile values of the general
population BASFI can be used as benchmarks to define
disease-attributable disability in clinical populations.
However, until now, BASFI scores of the general adult
population have not been reported, nor have BASFI
scores of patients with AS been compared with those of
the general population.
Conclusion
This study suggests that the discriminating power of
BASFI is considered good at any age. The best cutoff of
this index increased as age increases as functional dis-
ability is associated in part with lifestyle choices and
increases with age. The normative values of BASFI that
we have presented could be used as a reference bench-
mark for clinical studies using this index of disability.
The main limitation lies in the procedures used to
select subjects, who were all volunteers and ambulatory.
Another limitation of this study was the small number
of healthy subjects from the general population. There-
fore, we were not able to give reference values of BASFI
score for all adult age groups. Then, reference values of
BASFI should be evaluated in other populations and
countries to confirm our results.
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